Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bis(alpha-furancarboxylato)oxovanadium composition for treatment of diabetes

A technology of furocarboxylic acid and diabetes drug, which is applied in the directions of drug combination, medical preparations containing active ingredients, metabolic diseases, etc., can solve the problems such as insufficient control of blood sugar, complex etiology and pathogenesis, and induction of cardiovascular diseases, etc. To achieve the effect of improving drug stability, accurate dosage and low cost

Inactive Publication Date: 2013-09-25
KUNMING MEDICAL UNIVERSITY +2
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009]The etiology and pathogenesis of diabetes are complex, long-term medication not only has the blood sugar of quite a few patients not yet effectively controlled, but also insulin secretion promoters will aggravate the already damaged β-cell burden, causing hypoglycemia, and inducing cardiovascular disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bis(alpha-furancarboxylato)oxovanadium composition for treatment of diabetes
  • Bis(alpha-furancarboxylato)oxovanadium composition for treatment of diabetes
  • Bis(alpha-furancarboxylato)oxovanadium composition for treatment of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Embodiment 1 - tablet:

[0061] 1.1 [Prescription] BFOV 10 g, metformin 50 g, lactose 30 g, microcrystalline cellulose 90 g, micronized silica gel 3 g, magnesium stearate 1 g, low-substituted hydroxypropyl cellulose 10 g, povidone 30 6 g.

[0062] [Preparation] Put BFOV, metformin, lactose, povidone, microcrystalline cellulose, etc. in a dry granulator and stir, and the obtained granules are mixed with magnesium stearate and low-substituted hydroxypropyl cellulose and passed through a 16-mesh sieve. The granules prepared by the above method are compressed into disc-shaped or heterogeneous tablet-shaped preparations, including sugar-coated tablets, film tablets and the like. Tablet weight: 0.1g / tablet.

[0063] 1.2 [Prescription] BFOV 10 g, metformin 200 g, lactose 40 g, microcrystalline cellulose 110 g, micropowder silica gel 6 g, magnesium stearate 2 g, low-substituted hydroxypropyl cellulose 20 g, povidone 30 12 g.

[0064] [Preparation] Put BFOV, metformin, lactose...

Embodiment 2

[0067] Embodiment 2——granule:

[0068]2.1 [Prescription] Bis(α-furanoic acid) vanadyl (BFOV) 10 g, metformin 50 g, sodium saccharin 10 g, croscarmellose sodium 10 g, microcrystalline cellulose 75 g, micronized silica gel 3 g, Sucrose fine powder 15 g, orange flavor 6 g, sodium bicarbonate 15 g, sodium lauryl sulfate 6 g.

[0069] [Preparation] After passing BFOV, metformin and sucrose fine powder through a 16-mesh sieve, put it in a mixer and mix it with sodium saccharin. The mixture is granulated with povidone ethanol solution, and after drying, it is sieved through 30 meshes to sieve the whole granule and mix with the remainder of the prescription. Sodium bicarbonate is passed through a 30-mesh sieve, orange flavor and sodium lauryl sulfate are passed through a 60-mesh sieve. Whole grain, graded. Loading capacity 0.1g / bag.

[0070] 2.2 [Prescription] BFOV 10 g, metformin 200 g, saccharin sodium 10 g, croscarmellose sodium 20 g, microcrystalline cellulose 94 g, micropowde...

Embodiment 3

[0074] Embodiment 3——capsules:

[0075] 3.1 [Prescription] BFOV 10 g, metformin 50 g, micronized silica gel 3 g, magnesium stearate 1 g, microcrystalline cellulose 136 g.

[0076] [Preparation] Pass the fine powder of BFOV, metformin and dressing through a 16-mesh sieve, and fill it into hollow capsules. According to the nature of the packaging material, it can be divided into hard capsules or enteric-coated capsules. Capsule weight: 0.1 g / capsule.

[0077] 3.2 [Prescription] BFOV 10 g, metformin 200 g, micronized silica gel 6 g, magnesium stearate 2 g, microcrystalline cellulose 182 g.

[0078] [Preparation] Pass the fine powder of BFOV, metformin and dressing through a 16-mesh sieve, and fill it into hollow capsules. According to the nature of the packaging material, it can be divided into hard capsules or enteric-coated capsules. Capsule weight: 0.2 g / capsule.

[0079] 3.3 [Prescription] BFOV 10 g, metformin 500 g, micronized silica gel 15 g, magnesium stearate 5 g, mi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a bis(alpha-furancarboxylato)oxovanadium composition for treatment of diabetes, and belongs to the field of pharmaceutics. The composition of the invention is prepared from bis(alpha-furancarboxylato)oxovanadium and melbine at a ratio of 1:5 to 50, and appropriate accessories are added to produce pills, powders and capsules. Recommended dosage for human is 10mg: (50 to 500mg) per day, and preferable dosage is 10mg:200mg or 10mg:500mg. The results of animal experiment show that: the composition is capable of decreasing blood glucose levels of alloxan-induced diabetic mice, streptozotocin-induced diabetic mice and high fat feed-induced insulin-resistant mice greatly, improving lipid metabolism disorders of insulin-resistant mice, and increasing insulin sensitivity.

Description

technical field [0001] The invention belongs to medicine and preparation, in particular to the composition and preparation of bis(alpha-furanoic acid)vanadyl for preventing and treating diabetes. Background technique [0002] In 2005, the organic vanadium antidiabetic drug BEOV developed by British Columbia University in Canada [0003] For the first time, it entered phase I clinical trial in the UK, which has the effect of inhibiting protein tyrosine phosphatase (PTPase), and is a new type of insulin-enhancing agent (insulin-enhancing agent), which can be used for treatment and relief Type 1 and Type 2 diabetes. In 2002, the inventor proposed the invention titled "Vanadium Compound and Its Preparation and Application" (ZL00128053.8), including bis(α-furanoic acid)vanadyl [BFOV, VO-FA] as the vanadium compound used for treating diabetes ], its structural formula is as follows: [0004] [0005] Before 2009, our research showed that BFOV can significantly reduce blood s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/555A61K31/155A61P3/10
Inventor 高丽辉李玲申竹芳刘伟平谌喜珠李林忆李云巍
Owner KUNMING MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com